2024-19726. Medical Devices; Orthopedic Devices; Classification of the Intervertebral Body Graft Containment Device
Table 1—Intervertebral Body Graft Containment Device Risks and Mitigation Measures
Identified risks to health Mitigation measures Adverse tissue reaction Design characteristics, Biocompatibility evaluation, Sterilization/reprocessing validation, and Labeling. Infection Sterilization/reprocessing validation and Labeling. Loosening/migration due to device failure or failure at the bone-implant interface Design characteristics, Clinical performance testing, Non-clinical performance testing, Biocompatibility evaluation, and Labeling. Tissue injury Labeling. Pseudarthrosis due to device failure or failure at the bone-implant interface Clinical performance testing, Non-clinical performance testing, Biocompatibility evaluation, and Labeling. Adverse clinical sequelae Clinical performance testing and Labeling. Use error/Improper device use Labeling.
Document Information
- Effective Date:
- 9/3/2024
- Published:
- 09/03/2024
- Department:
- Food and Drug Administration
- Entry Type:
- Rule
- Action:
- Final amendment; final order.
- Document Number:
- 2024-19726
- Dates:
- This order is effective September 3, 2024. The classification was applicable on September 18, 2020.
- Pages:
- 71157-71159 (3 pages)
- Docket Numbers:
- Docket No. FDA-2024-N-3994
- Topics:
- Medical devices
- PDF File:
- 2024-19726.pdf
- CFR: (1)
- 21 CFR 888